All 19 non-breast tumors showed ERBB2 amplification (estimated CN above 3.0) but their HER2 IHC score varied, indicating that NGS-derived CN amplification and IHC scoring systems are not as concordant in non-breast cancers as in breast cancers. The gene discussed is ERBB2; the disease is breast cancer.